Screener
Vertex Pharmaceuticals VRTX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's restricted cash?
- Vertex Pharmaceuticals (VRTX) reported restricted cash of $12M in Q1 2026.
- How has Vertex Pharmaceuticals's restricted cash changed year-over-year?
- Vertex Pharmaceuticals's restricted cash increased by 12.1% year-over-year, from $10.7M to $12M.
- What is the long-term trend for Vertex Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's restricted cash has grown at a 33.8% compound annual growth rate (CAGR), from $700K to $3M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Vertex Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude